{ "items": [ "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Liz\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Congratulations new NDM professors\n

\n\n\n\n

\n \n 30 October 2020\n \n

\n\n \n

\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n LOMWRU\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n

\n \n\n \n \n \n

The University of Oxford has awarded CTMGH two new Professors. Elisabeth Ashley - UK-trained physician who specialises in infectious diseases and medical microbiology & virology, and Director of the Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU) in Lao PDR since 2019, Liz is conferred the title of Professor of Tropical Medicine. Stuart Blacksell - Senior Research Scientist based at the Mahidol-Oxford Tropical Medicine Research Unit (MORU) in Thailand, Stuart is conferred the title of Professor of Tropical Microbiology.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Profesor\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n British Pharmacology Society honours Joel Tarning\n

\n\n\n\n

\n \n 28 October 2020\n \n

\n\n \n

\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n

\n \n\n \n \n \n

We are pleased to announce that Prof Joel Tarning has been awarded the biennial Grahame-Smith Prize by the British Pharmacological Society for outstanding contributions to clinical pharmacology. Joel has headed MORU's Clinical Pharmacology Department since 2012. Since then, the Department has grown into large, productive group that conducts laboratory- and computer-based pharmacology research.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Map\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Oxford Global Research\n

\n\n\n\n

\n \n 23 October 2020\n \n

\n\n \n

\n \n\n \n \n \n \n COMRU\n \n \n \n \n MOCRU\n \n \n \n \n MORU Bangkok\n \n \n \n \n SMRU\n \n \n\n \n\n\n

\n \n\n \n \n \n

Oxford is world-famous for research excellence and home to some of the most talented people from across the globe. To showcase our global research, the University launched a Global Research Map, highlighting areas of research we are conducting overseas.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Thai\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Parenting for lifelong health for young children, project led by MORU Bioethics & Engagement Amalee McCoy\n

\n\n\n\n

\n \n 14 October 2020\n \n

\n\n \n

\n \n\n \n \n \n \n MORU Bangkok\n \n \n \n \n Public Engagement\n \n \n \n \n Video\n \n \n\n \n\n\n

\n \n\n \n \n \n

The University of Oxford, MORU, the University of Cape Town, the Thai Ministry of Public Health, and UNICEF Thailand worked together to promote lifelong health and well-being, and prevent violence against children. Led by Amalee McCoy from MORU Department of Bioethics & Engagement, this project involved the cultural adaptation and testing of an evidence-based parenting intervention for low-income families with children aged 2-9 living in Udon Thani, Thailand.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Mo\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n MORU students Mo Yin and Myo Maung Maung Swe receive NDM awards\n

\n\n\n\n

\n \n 14 October 2020\n \n

\n\n \n

\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n MOCRU\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n

\n \n\n \n \n \n

MORU\u2019s Mo Yin and MOCRU\u2019s Myo Maung Maung Swe were awarded a prize by the NDM\u2019s Graduate Studies Committee. Very competitive awards, the prizes are given annually to current or recently graduated students of NDM supervisors on the basis of their publication record, the impact and novelty of their research, references, and research within their department.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Mother\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Large scale systematic review details causes of non-malarial febrile illnesses globally and identifies research priorities\n

\n\n\n\n

\n \n 21 September 2020\n \n

\n\n \n

\n \n\n \n \n \n \n COMRU\n \n \n \n \n LOMWRU\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n

\n \n\n \n \n \n

A series of articles that set out to explore the global distribution of infections that cause non-malarial febrile illness has been published in BMC Medicine. The series brings together the results of large-scale systematic reviews of the causes of fever in Africa, Latin America, and Southern and South-Eastern Asia, and has helped identify major knowledge gaps, geographical differences, priority areas for diagnostics research and development, and enabled the most comprehensive systematic review of literature to date.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Paul\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Professor Paul Newton wins the Helen Clark-JoPPP Award\n

\n\n\n\n

\n \n 15 September 2020\n \n

\n\n \n

\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n LOMWRU\n \n \n\n \n\n\n

\n \n\n \n \n \n

We are delighted to announce that Professor Paul Newton has won the Helen-Clark-JoPPP Award for Pharmaceutical Policy and Practice Research. This award is based on the scientific merit of his work, as well as its impact on patients, decisions makers, and on governments. It recognizes the talents of exceptional researchers who are making a significant contribution to the field of pharmaceutical policy and practice.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Three\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Microscopy standards to harmonise methods for malaria clinical research studies\n

\n\n\n\n

\n \n 10 September 2020\n \n

\n\n \n

\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n

\n \n\n \n \n \n

Research Malaria Microscopy Standards (ReMMS) applicable to malaria clinical research studies have been published in Malaria Journal. The paper describes the rationale for proposed standards to prepare, stain and examine blood films for malaria parasites.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Hand\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Hydroxychloroquine doses in COVID-19 prevention trials should be safe, study finds. Now let\u2019s find out if they\u2019re effective.\n

\n\n\n\n

\n \n 10 September 2020\n \n

\n\n \n

\n \n\n \n \n \n \n COPCOV\n \n \n \n \n COVID-19\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n

\n \n\n \n \n \n

As the world waits impatiently for a COVID-19 vaccine, an exhaustive review of hydroxychloroquine and chloroquine pharmacology suggests that the doses used in COVID-19 prevention trials are safe, say University of Oxford affiliated researchers in a study published in PLoS Medicine.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Female\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Five years at the top: Oxford retains first place in World University Rankings\n

\n\n\n\n

\n \n 3 September 2020\n \n

\n\n \n

\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n General\n \n \n\n \n\n\n

\n \n\n \n \n \n

Oxford University\u2019s enduring global reputation, cutting edge research and unique teaching environment have helped retain first place in the Times Higher Education World University Rankings for a fifth consecutive year. THE rankings use 13 separate performance indicators to cover universities\u2019 core missions across teaching, research, knowledge transfer and international outlook. The award follows a year when the University of Oxford has been at the centre of international attention for its work on finding a vaccine for COVID-19 as well as taking a leading role in trialling therapeutic drugs and antibody testing.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Person\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Hydroxychloroquine is being discarded prematurely in COVID-19 prevention\n

\n\n\n\n

\n \n 6 August 2020\n \n

\n\n \n

\n \n\n \n \n \n \n COPCOV\n \n \n \n \n COVID-19\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n

\n \n\n \n \n \n

Hydroxychloroquine could still prevent COVID-19 and save tens of thousands of lives around the world, say leading scientific researchers. While it doesn\u2019t work in treatment of hospitalised patients, it could still prevent infections. However, fraudulent data, unjustified extrapolation and exaggerated safety concerns together with intense politicisation and negative publicity may stop COPCOV, the only large, global clinical trial testing hydroxychloroquine in COVID-19 prevention, from ever finding out.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Local\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Drug-resistant enteric fever, antibiotics and the need for clean water\n

\n\n\n\n

\n \n 5 August 2020\n \n

\n\n \n

\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n

\n \n\n \n \n \n

Blog by Professor Christiane Dolecek. Antimicrobial resistance is a critical problem in enteric fever. Drug-resistant infections can have severe consequences, and slowing their spread requires our urgent attention. The most important intervention is to reduce the number of infections; vaccines are a critical tool, alongside surveillance and diagnosis. To achieve this control, strong partnerships between WHO, governments, NGOs, academia, private sector and communities are needed.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Africa\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Medicine Quality Scientific Literature Surveyor\n

\n\n\n\n

\n \n 21 July 2020\n \n

\n\n \n

\n \n\n \n \n \n \n LOMWRU\n \n \n\n \n\n\n

\n \n\n \n \n \n

IDDO and MORU released its Medicine Quality Scientific Literature Surveyor. The surveyor delivers summaries of published scientific reports on the quality of the classes of essential medicines listed below, across regions and over time. We hope it will help medicine regulators, scientists, health professionals, purchasers and officials fill critical information gaps.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Mavuto\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n New Oxford academic titles for MORU colleagues\n

\n\n\n\n

\n \n 14 July 2020\n \n

\n\n \n

\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n COMRU\n \n \n \n \n LOMWRU\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n

\n \n\n \n \n \n

The results of the University of Oxford\u2019s Recognition of Distinction exercise for Associate Professor and University Research Lecturer are in, and I am delighted to announce that the University has conferred titles on the following MORU staff:

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Hand\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n UK regulator gives green light to clinical trial of hydroxychloroquine to prevent Covid-19 in healthcare workers\n

\n\n\n\n

\n \n 30 June 2020\n \n

\n\n \n

\n \n\n \n \n \n \n COPCOV\n \n \n \n \n COVID-19\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n

\n \n\n \n \n \n

The UK regulator MHRA announced on 26 June that it would again permit recruitment to the COPCOV COVID-19 prevention clinical trial. The MHRA decision came 5 weeks after it reacted immediately to the now-discredited paper published in The Lancet suggesting harms with hydroxychloroquine, and paused recruitment of UK participants. But The Lancet paper was based on fabricated data and was swiftly retracted. After this interruption, recruitment around the globe to COPCOV can now resume.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Coronavirus\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n COVID-19 prevention and treatment: a critical analysis of chloroquine and hydroxychloroquine clinical pharmacology\n

\n\n\n\n

\n \n 20 June 2020\n \n

\n\n \n

\n \n\n \n \n \n \n COPCOV\n \n \n \n \n COVID-19\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n

\n \n\n \n \n \n

Paper by NJ White et al, PLoS Medicine, in press. Using available pharmacokinetic information from healthy volunteers, the treatment of malaria, the chronic treatment of rheumatological conditions and the toxicokinetics of chloroquine in self-poisoning, the authors predict exposures and safety margins in the high dose chloroquine and hydroxychloroquine COVID-19 prevention and treatment regimens currently under evaluation. These regimens are predicted to have reasonable safety margins. Large, well conducted randomised clinical trials with appropriate monitoring are required to determine if chloroquine and hydroxychloroquine have preventive or treatment efficacy in COVID-19 and acceptable safety. Current recommendations for their use outside of clinical trials are not justified at this time.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Composite\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Major medical journals retract Covid-19 studies\n

\n\n\n\n

\n \n 9 June 2020\n \n

\n\n \n

\n \n\n \n \n \n \n COPCOV\n \n \n \n \n COVID-19\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n

\n \n\n \n \n \n

On 4 June 2020, after a week of increasing scientific concern and scrutiny, first The Lancet, then the New England Journal of Medicine, retracted studies that were based on inaccessible data. The studies have been extremely damaging to chloroquine and hydroxychloroquine COVID-19 clinical trials around the globe. MORU researchers played a key role in bringing this scandal to light, whose consequences continue to play out.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"The\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Clinical trials on hydroxychloroquine/ chloroquine in COVID-19. Statement in response to damaging recent events\n

\n\n\n\n

\n \n 5 June 2020\n \n

\n\n \n

\n \n\n \n \n \n \n COPCOV\n \n \n \n \n COVID-19\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n

\n \n\n \n \n \n

On 4 June 2020, after a week of increasing scientific concern and scrutiny, first The Lancet, then a little over an hour later the New England Journal of Medicine, retracted studies that were based on inaccessible data, provided by the Surgisphere corporation. The studies have been extremely damaging to chloroquine and hydroxychloroquine COVID-19 clinical trials around the globe. Here is MORU\u2019s statement in response to these events.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Hand\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n An open letter to Richard Horton, editor of The Lancet regarding Mehra et al\n

\n\n\n\n

\n \n 29 May 2020\n \n

\n\n \n

\n \n\n \n \n \n \n COPCOV\n \n \n \n \n COVID-19\n \n \n \n \n General\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n

\n \n\n \n \n \n

The results of Mehra et al in The Lancet have had a considerable impact on public health practice and research, halted trials and caused considerable concern to participants and patients enrolled in randomised controlled trials (RCTs). This has led many researchers around the world to scrutinise in detail the publication and outline their concerns in this letter to Richard Horton, editor of The Lancet.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"COPCOV\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n COPCOV study paused\n

\n\n\n\n

\n \n 26 May 2020\n \n

\n\n \n

\n \n\n \n \n \n \n COPCOV\n \n \n \n \n COVID-19\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n

\n \n\n \n \n \n

We received notice from the UK's MHRA (Medicines and Healthcare Products Regulatory Agency) to pause for now new enrolment into our COPCOV study. We responded promptly to the MHRA, addressing their concerns in detail and await their decision. For now, COPCOV study enrolment is paused around the globe. The safety of our participants is our first priority, as is preventing illness in front-line healthcare workers.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Health\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Global clinical trial of 40,000+ healthcare workers begins to test in UK if chloroquine and hydroxychloroquine can prevent COVID-19\n

\n\n\n\n

\n \n 21 May 2020\n \n

\n\n \n

\n \n\n \n \n \n \n COPCOV\n \n \n \n \n COVID-19\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n

\n \n\n \n \n \n

A global study to test if either chloroquine or hydroxychloroquine can prevent COVID-19 in vital frontline healthcare workers will open to UK participants at hospital sites in Brighton and Oxford today.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Surgical\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n SEBCOV study launched today\n

\n\n\n\n

\n \n 1 May 2020\n \n

\n\n \n

\n \n\n \n \n \n \n COVID-19\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n

\n \n\n \n \n \n

The SEBCOV study aims to produce evidence to inform public health measures such as communications, quarantine, self-isolation, social distancing, and travel restrictions for the COVID-19 pandemic. This study is run in four countries: UK, Thailand, Italy and Malaysia.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Rural\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n PAL forest malaria prophylaxis study begins in Cambodia\n

\n\n\n\n

\n \n 29 April 2020\n \n

\n\n \n

\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n

\n \n\n \n \n \n

The Epidemiology Department of MORU and National Malaria Control Programme, Cambodia (CNM) have begun to implement a study to assess the efficacy of prophylaxis with artemether-lumefantrine (PAL) against forest malaria in Siem Pang District, north-eastern Cambodia bordering Laos.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Screenshot\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n GroupMappers create real-time COVID-19 Bangladesh dashboard\n

\n\n\n\n

\n \n 24 April 2020\n \n

\n\n \n

\n \n\n \n \n \n \n COVID-19\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n

\n \n\n \n \n \n

The impact of COVID-19 is quite evident at present \u2013 entire countries and cities are under lockdown, offices and industries shut and academia at a standstill. However, many people in Bangladesh remain unaware or indifferent to the warnings and safety protocols that ought to be followed to stop COVID-19\u2019s spread. Since enforcing social distancing in a densely populated country like Bangladesh is very challenging, making people aware and maintenance of hygiene are the main means to stop the spread of COVID-19.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Nick\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n COPCOV Covid-19 study prepares to begin participant enrolment\n

\n\n\n\n

\n \n 23 April 2020\n \n

\n\n \n

\n \n\n \n \n \n \n COMRU\n \n \n \n \n COPCOV\n \n \n \n \n COVID-19\n \n \n \n \n LOMWRU\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n

\n \n\n \n \n \n

Less than a month after it was announced, the MORU-led COPCOV study has made quick progress and expects to begin enrolling participants by the end of April.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Coronavirus\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Global call for strategic planning for COVID-19 medical products\n

\n\n\n\n

\n \n 10 April 2020\n \n

\n\n \n

\n \n\n \n \n \n \n COVID-19\n \n \n \n \n LOMWRU\n \n \n\n \n\n\n

\n \n\n \n \n \n

Global health experts have united in a call for governments and international organisations around the world to plan strategically for the coordinated production, equitable distribution and surveillance of COVID-19 medical products to ensure access to quality-assured medications for everyone.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Screenshot\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n BBC World News interviews Nick White on chloroquine and hydroxychloroquine for COVID-19: \u201cThese drugs are not harmless, they\u2019re dangerous in over-dose.\u201d\n

\n\n\n\n

\n \n 6 April 2020\n \n

\n\n \n

\n \n\n \n \n \n \n COPCOV\n \n \n \n \n COVID-19\n \n \n \n \n MORU Bangkok\n \n \n \n \n Public Engagement\n \n \n \n \n Video\n \n \n\n \n\n\n

\n \n\n \n \n \n

There are currently no proven vaccines or drugs to prevent COVID-19. In this BBC World News interview, MORU\u2019s Prof Sir Nick White explains why the only way to find out if chloroquine and hydroxychloriquine work against COVID-19 is via randomised, clinical trials and how the hype over chloroquine negatively affects people with lupus and rheumatoid arthritis.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Screenshot\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n COVID-19 Therapeutics Accelerator awards $20 million in initial grants to fund clinical trials\n

\n\n\n\n

\n \n 30 March 2020\n \n

\n\n \n

\n \n\n \n \n \n \n COPCOV\n \n \n \n \n COVID-19\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n

\n \n\n \n \n \n

Researchers at MORU and two institutions in the US (University of Washington and La Jolla Institute for Immunology) receive grants from the COVID-19 Therapeutics Accelerator, a large-scale initiative launched by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard to speed the development of and access to therapies for COVID-19.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"People\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Triple drug combinations effective against drug-resistant malaria\n

\n\n\n\n

\n \n 11 March 2020\n \n

\n\n \n

\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n

\n \n\n \n \n \n

Adding a third anti-malaria drug to current artemisinin-combination therapies (ACTs) provides effective treatment against multidrug-resistant falciparum malaria in Southeast Asia, say Oxford researchers in a study in The Lancet. Using TACTs should extend current malaria drugs so drug-resistant malaria doesn't kill millions more and derail hopes of controlling and eliminating malaria.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Health\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Why is WHO failing women with falciparum malaria in the first trimester of pregnancy?\n

\n\n\n\n

\n \n 6 March 2020\n \n

\n\n \n

\n \n\n \n \n \n \n SMRU\n \n \n\n \n\n\n

\n \n\n \n \n \n

From The Lancet Correspondence. In the opening to the 2019 World Malaria Report, entitled Leaving no one behind in the march to a malaria free world, the WHO\u2019s Director-General notes that the scourge of malaria continues to strike hardest against pregnant women and children in Africa.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Dr\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Women and Girls in Science Day 2020\n

\n\n\n\n

\n \n 11 February 2020\n \n

\n\n \n

\n \n\n \n \n \n \n General\n \n \n\n \n\n\n

\n \n\n \n \n \n

The International Day of Women and Girls in Science recognises and celebrates the critical role played by women but also aims to promote their full and equal access to participation in science. However, despite more women than ever working across the sciences, it is still a male-dominated field with only 30% of female researchers, according to UNESCO. IDDO asked colleagues across their networks for their views. How we could encourage more women into science? And what changes are needed in order to keep them in science?

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Painting\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Art exhibition on substandard and falsified medicines comes to Bangkok\n

\n\n\n\n

\n \n 10 January 2020\n \n

\n\n \n

\n \n\n \n \n \n \n MORU Bangkok\n \n \n \n \n Public Engagement\n \n \n\n \n\n\n

\n \n\n \n \n \n

When we are ill, we expect our medicines to work as intended. But what if they do not contain the ingredients listed on the packaging? The Pharmacide Arts exhibition \u201cWhat\u2019s in your medicines?\u201d showcases the original artwork of 11 South East Asian artists. The exhibition is open to the public from 26th-28th January 2020 at the Mandarin Hotel, Bangkok, from 10 am \u2013 5 pm.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Nepalese\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Global study highlights the extent and impact of drug-resistant enteric fever and the urgent need for new approaches\n

\n\n\n\n

\n \n 23 December 2019\n \n

\n\n \n

\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n

\n \n\n \n \n \n

A new study conducted by Christiane Dolecek and colleagues analysed data on antimicrobial resistance of the bacteria Salmonella Typhi and Salmonella Paratyphi, from around the globe, spanning the time from 1990 to 2018. The study highlights the impact of drug resistance and the urgent need for interventions.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Joel\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Joel Tarning wins Ashford award at ASTMH 2019\n

\n\n\n\n

\n \n 22 November 2019\n \n

\n\n \n

\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n

\n \n\n \n \n \n

Professor Joel Tarning received a Bailey K. Ashford Medal at the ASTMH 2019 Conference. The medal is awarded annually for distinguished work in tropical medicine by an early- to mid-career ASMTH member. Joel is Head of Clinical Pharmacology at MORU and his work focuses on applying pharmacokinetic-phamacodynamic modelling to optimise antimalarial drug therapies, in particular for at-risk groups such as malnourished children and pregnant women.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Oxford\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Oxford named best for medicine for ninth consecutive year\n

\n\n\n\n

\n \n 19 November 2019\n \n

\n\n \n

\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n General\n \n \n\n \n\n\n

\n \n\n \n \n \n

Oxford University has been ranked as the world's best institution for medical and health teaching and research for the ninth consecutive year in the latest Times Higher Education World University Rankings. The ranking is based on criteria measuring teaching, research, industry income, international outlook and citations, which are combined to provide a comparison of universities worldwide.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Hand-held\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Call for global action on medicine quality\n

\n\n\n\n

\n \n 7 November 2019\n \n

\n\n \n

\n \n\n \n \n \n \n LOMWRU\n \n \n\n \n\n\n

\n \n\n \n \n \n

Noting that substandard and falsified medical products (including medicines, vaccines, biologics, and diagnostics) represent a significant and growing threat to human health, The Lancet Global Health published 'The Global access to quality-assured medical products: the Oxford Statement and call to action'.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"A\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Artists explore the problems of poor quality and fake medicines\n

\n\n\n\n

\n \n 16 October 2019\n \n

\n\n \n

\n \n\n \n \n \n \n LOMWRU\n \n \n \n \n Public Engagement\n \n \n\n \n\n\n

\n \n\n \n \n \n

When we are ill, we trust that the medicines that we take will make us feel and be better. But what if our pills do not contain the ingredients listed on the packaging? The art exhibition \u2018What\u2019s in your medicines?\u2019 explores how substandard and falsified (\u2018fake\u2019) medicines can affect our health, by showcasing the striking and original artwork of 12 South East Asian artists.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Sassy\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Congratulations new TropMed professors\n

\n\n\n\n

\n \n 9 October 2019\n \n

\n\n \n

\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n

\n \n\n \n \n \n

Oxford Medical Sciences Divisional Panel has conferred the title of Professor on three members of our Centre. Ben Cooper - Professor of Epidemiology, Sassy Molyneux - Professor of Global Health and Piero Olliaro - Professor of Poverty Related Infectious Diseases were awarded these titles in recognition of their distinction in their respective fields and contributions to the research, teaching and administration of the Department and we congratulate them on their success!

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Researcher\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n New research supports co-administration of primaquine with artemisinin-based combination therapies for P. vivax malaria\n

\n\n\n\n

\n \n 8 October 2019\n \n

\n\n \n

\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n

\n \n\n \n \n \n

An individual patient data meta-analysis of 2,017 patients from 19 studies has found a high risk of recurrence following treatment of P. vivax malaria with artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP) unless they are co-administered with primaquine. The research supports recommendations that these artemisinin-based combination therapies (ACT) should be combined with primaquine.

\n \n\n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n
\n \n\n \n
\n
\n \n\n \n \n \"Peter\n \n \n\n\n
\n \n
\n \n\n\n
\n \n\n
\n\n \n\n

\n Nobel Prize for Medicine awarded to NDM Professor Sir Peter Ratcliffe\n

\n\n\n\n

\n \n 7 October 2019\n \n

\n\n \n

\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n General\n \n \n\n \n\n\n

\n \n\n \n \n \n

Professor Sir Peter J Ratcliffe, Director for the Target Discovery Institute within the Nuffield Department of Medicine at Oxford University and Director of Clinical Research at Francis Crick Institute, London, has today been announced as a winner of the Nobel Prize in Physiology or Medicine.

\n \n\n
\n\n
\n\n
\n\n\n" ], "more": "\n\n \n \n Load More\n \n \n\n", "msg": "" }